In consultation with the OARSI Corporate Council, a new corporate membership structure has been developed. The levels of membership are:
$10,000 – One year membership
$17,000- Two year membership (fully payable in year one- a savings of $1,500 per year)
$22,500- Three year membership (fully payable in year one- a savings of $2,500 per year)
A number of potential initiatives, with benefits to industry and the field of OA, are discussed during the OARSI Corporate Council meeting at the Congress.Recent examples include
- Course to train Principal Investigators on OA clinical trial design (Las Vegas, 2017)
- Patient and Provider Educational Materials: to be available and downloadable on the OARSI website
- Accelerated Approvals According to SUBPART H – What does that mean for the OA field: A Scientific and Regulatory Perspective and Discussion (Liverpool, 2018)
Becoming a corporate member includes numerous benefits including,:
- Opportunity to serve on certain OARSI committees and task forces to identify new initiatives
- Invitation to semi annual Industry Council meetings and teleconferences with the OARSI leadership to discuss ongoing projects and potential for future initiatives
- Reduced exhibit booth fees during the OARSI World Congress
- Bi-monthly OARSI newsletter
- Access to members only section of OARSI Website; access to annual OARSI World Congress presentations
- Reduced rate to post job opening and search CV’s on the OARSI Job Board
- Recognition of corporate membership: OARSI World Congress signage,Printed materials provided to Congress delegates,Acknowledgement on OARSI website
It is only through the financial assistance of industry partners that OARSI is able to move the field of osteoarthritis forward and bring the world’s OA experts together at the OARSI Annual World Congress. Please consider joining today.
Click here to complete a very short application
For additional information contact: email@example.com or tel: +1-856-642-4215
2018 Industry Partners
Merck is the North America biopharma business of Merck KGaA, Darmstadt, Germany – a leading science and technology company – focused exclusively on specialty care. EMD Serono has deep expertise in neurology, fertility and endocrinology, and a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas
Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. The company is currently advancing a portfolio of injectable drug candidates. Our lead program, ZilrettaTM (also known as FX006), is an intra-articular sustained release corticosteroid for patients with moderate to severe osteoarthritis (OA) pain.
Samumed is a leader in medical research and development for tissue-level regeneration. With our platform's origins in small molecule-based Wnt pathway modulation, we develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.
Thuasne is a globally recognized creator, manufacturer and distributor
of wearable medical devices, including braces, supports and medical garments.
Founded in 1847, Thuasne envisions #Medweartech as the strategic intersection of
medicine, materials and digital technologies.Thuasne provides "wings for your health" by elevating each person's active involvement in their own health and medical care.
Pre Competitive Consortium for OA
The current regulatory approach throughout the world creates formidable challenges for the development of structure modifying drugs for OA. The ability to capitalize on imaging or chemical biomarkers of OA as surrogate markers to demonstrate disease modification with subsequent temporal linkage to clinically relevant outcomes is limited due to the requirement that surrogate markers be used only in the development of drugs for very severe or life threatening diseases.
In disorders that evolve over years, or even decades, it is critical to establish appropriate surrogate markers that will help predict outcomes. This effort is in its infancy with regard to osteoarthritis research. Energizing the next phase of biomarker development will require both ensuring an understanding of the stakes involved among regulators and supporting the efforts of researchers to develop new surrogate markers.
PCCOA Initiative will undertake the important work to establish the importance of OA as a serious condition for which there are currently no satisfactory therapies according to the FDA definition – “a disease or condition associated with morbidity that has substantial impact on day-to-day functioning”. A White paper on OA as a serious disease is underway with Lyn March and Gillian Hawker as co-Chairs of this working group.
Developing a standard definition of OA for improving communication about the disease among interest groups and agencies.
The long-term goal to gain acceptance of surrogates (e.g. MRI) as clinical endpoints in OA trials. READ MORE
Update to the OARSI Treatment Guidelines for Non Surgical Management of Knee OA- to be published late 2018